CLINICAL PROFILE AND TREATMENT RESPONSE TO SOFOSBUVIR-VELPATASVIR REGIMEN AND ITS IMPACT ON THE QUALITY OF LIFE IN CHRONIC HEPATITIS C PATIENTS

AJIT PRATAP SINGH; PANKAJ ASATI; KANISHK YADAV

doi:10.22159/ijpps.2023v15i9.48349

Authors

AJIT PRATAP SINGH Department of Pharmacology, Netaji Subhash Chandra Medical College and Hospital, Jabalpur-482003, Madhya Pradesh, India
PANKAJ ASATI Department of Pharmacology, Netaji Subhash Chandra Medical College and Hospital, Jabalpur-482003, Madhya Pradesh, India
KANISHK YADAV Department of Pharmacology, Netaji Subhash Chandra Medical College and Hospital, Jabalpur-482003, Madhya Pradesh, India

DOI:

https://doi.org/10.22159/ijpps.2023v15i9.48349

Keywords:

Chronic Hepatitis C, Direct-acting antiviral, Sofosbuvir, Velpatasvir, Quality of Life

Abstract

Objective: Chronic Hepatitis C infection is one of the major global contributors to liver-related morbidity and mortality. Successful antiviral therapy with the direct-acting antiviral combination sofosbuvir-velpatasvir has shown to improve survival, liver-related outcomes, all-cause mortality, and even reverse fibrosis. We evaluated the treatment response of this regimen in terms of its impact on the Quality of life of patients during and after the therapy.

Methods: This is an Observational, prospective, descriptive study of serologic HCV RNA-positive cases. Data on change in clinical, biochemical profile, and quality of life using 2 standardized questionnaires SF-36 and CLDQ was analyzed at baseline, 12 w from baseline, and 24 w after therapy cessation.

Results: 62 out of the 87 patients registered during the study completed the desired study duration. 95% achieved sustained virological response (SVR) at 12 w and 100% at 24 w from baseline. Improved clinical profile with symptom resolution and change in the biochemical parameters and quality-of-life scores was statistically significant (P value-<0.001 and 0.005) at 12 w from baseline and 24 w after therapy cessation, respectively.

Conclusion: Patients achieving SVR with sofosbuvir-velpatasvir have been shown to improve clinical profile with normalization in biochemical markers of liver disease, which is reflected in all the quality-of-life domains of SF-36 and CLDQ-HCV. However, long-term follow-up with larger sample size is required for improved study validity and to improve long-term liver-related outcomes.

Downloads

Download data is not yet available.

References

Pawlotsky JM. 148-acute viral hepatitis. In: Philadelphia: WB Saunders. Goldman’s Cecil Medicine. 25th ed. Goldman L, Schafer AI, editors; 2016. p. 1424-34. Available from: https://www.sciencedirect.com/science/article/pii/B9781437716047001500. [Last accessed on 27 Jul 2023]

Pawlotsky JM. 149-chronic viral and autoimmune hepatitis. In: Philadelphia: WB Saunders. Goldman’s Cecil Medicine. 25th ed. Goldman L, Schafer AI; 2016. p. 1434-41. Available from: https://www.sciencedirect.com/science/article/pii/B9781437716047001512. [Last accessed on 27 Jul 2023]

National Viral Hepatitis Control Program of India; 2018. Available from: https://www.nvhcp.mohfw.gov.in [Last accessed on 31 Oct 2022]

Satsangi S, Chawla YK. Viral hepatitis: Indian scenario. Med J Armed Forces India. 2016 Jul;72(3):204-10. doi: 10.1016/j.mjafi.2016.06.011, PMID 27546957.

Dienstag JL. Chronic hepatitis. In: New York: McGraw-Hill Education; 2022.

Ouzan D, Larrey D, Guyader D, Remy AJ, Riachi G, Heluwaert F. Evolution of hepatitis C virus treatment during the era of sofosbuvir-based therapies: a real-world experience in france. Dig Dis Sci. 2021 Mar;66(3):881-98. doi: 10.1007/s10620-020-06234-1, PMID 32303953.

Tamori A, Enomoto M, Kawada N. Recent advances in antiviral therapy for chronic hepatitis C. Mediators Inflamm. 2016;2016:6841628. doi: 10.1155/2016/6841628, PMID 27022210.

Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997 Nov 15;127(10):875-81. doi: 10.7326/0003-4819-127-10-199711150-00003, PMID 9382365.

Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018 Mar;38(3):443-50. doi: 10.1111/liv.13534, PMID 28756625.

Juanbeltz R, Castilla J, Martinez Baz I, O’Leary A, Sarobe M, San Miguel R. Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population. Qual Life Res. 2019 Jun 15;28(6):1477-84. doi: 10.1007/s11136-019-02111-1, PMID 30666549.

Bernuth S, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Dig Liver Dis. 2016 Mar;48(3):291-7. doi: 10.1016/j.dld.2015.09.015, PMID 26514736.

Zignego AL, Monti M, Gragnani L. Sofosbuvir/Velpatasvir for the treatment of hepatitis c virus infection. Acta Biomed. 2018;89(3):321-31. doi: 10.23750/abm.v89i3.7718, PMID 30333452.

Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N. Sofosbuvir and velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610, PMID 26571066.

Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS, Charlton M, ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015 Dec 31;373(27):2618–28. PMID: 26569658.

Lu M, Li J, Zhang T, Rupp LB, Trudeau S, Holmberg SD. Serum biomarkers indicate a long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection. Clin Gastroenterol Hepatol. 2016 Jul;14(7):1044-1055.e3. doi: 10.1016/j.cgh.2016.01.009, PMID 26804385.

George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5 y follow-up of 150 patients. Hepatology. 2009 Mar;49(3):729-38. doi: 10.1002/hep.22694, PMID 19072828.

Van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernandez-Rodriguez CM. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017 Mar;66(3):485-93. doi: 10.1016/j.jhep.2016.10.017, PMID 27780714.

Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014 Dec;21(12):930-7. doi: 10.1111/jvh.12224, PMID 24472062.

Narayanan K, Zachariah SA, Kurian VS. Aspartate platelet ratio index as a predictor of severity of fibrosis in chronic hepatits c. Asian Pharm Clin Res. 2023 Apr 7:69-83.

Vallet Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin Venier V. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007 Jul;46(1):32-6. doi: 10.1002/hep.21669, PMID 17567829.

Loaeza-del-Castillo A, Paz Pineda F, Oviedo Cardenas E, Sanchez Avila F, Vargas Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008;7(4):350-7. doi: 10.1016/S1665-2681(19)31836-8, PMID 19034235.

John Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009 Oct;104(10):2439-48. doi: 10.1038/ajg.2009.346, PMID 19568230.

Marcellin F, Roux P, Protopopescu C, Duracinsky M, Spire B, Carrieri MP. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol. 2017 Mar;11(3):259-68. doi: 10.1080/17474124.2017.1285227, PMID 28116926.

Goni Esarte S, Juanbeltz R, Martinez Baz I, Castilla J, San Miguel R, Herrero JI. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. Rev Esp Enferm Dig. 2019;111(6):445-52. doi: 10.17235/reed.2019.6063/2018, PMID 31066286.

Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease-specific questionnaire to measure health-related quality of life in patients with chronic liver disease. Gut. 1999 Aug;45(2):295-300. doi: 10.1136/gut.45.2.295, PMID 10403745.

Benjamin J, Mani K, Saraya A, Joshi YK. Translation and validation of the Hindi version of chronic liver disease questionnaire (CLDQ) for the assessment of health-related quality of life in patient with chronic liver disease in India. Trop Gastroenterol. 2016;37(2):112-22. doi: 10.7869/tg.335, PMID 30234280.

Juanbeltz R, Martinez Baz I, San Miguel R, Goni Esarte S, Cabases JM, Castilla J. Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLOS ONE. 2018;13(10):e0205277. doi: 10.1371/journal.pone.0205277. PMID 30300395.

Miyasaka A, Yoshida Y, Suzuki A, Takikawa Y. Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response. Qual Life Res. 2021 Dec 1;30(12):3501-9. doi: 10.1007/s11136-021-02874-6, PMID 34013404.

Chavalitdhamrong D, Tanwandee T. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. World J Gastroenterol. 2006 Sep 14;12(34):5532-5. doi: 10.3748/wjg.v12.i34.5532, PMID 17006994.

Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C. Sustained improvements in markers of liver disease severity after hepatitis C treatment. J Clin Exp Hepatol. 2020;10(2):114-23. doi: 10.1016/j.jceh.2019.09.001, PMID 32189926.

Sung JC, Bosh C, Wyatt B, Miller M, Harty A, Del Bello D. Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center. J Viral Hepat. 2020 Apr 1;27(4):350-9. doi: 10.1111/jvh.13234, PMID 31742821.

Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003 Aug;38(2):518-26. doi: 10.1053/jhep.2003.50346, PMID 12883497.